Study Finds Tenofovir Alafenamide Maintains Virological Response In Patients With Chronic Hepatitis B Virus Infection, Renal Or Hepatic Impairment

Healio (7/22, Burba) reports research found “tenofovir alafenamide was safe and maintained virological response in patients with chronic hepatitis B virus infection and renal or hepatic impairment who switched from tenofovir disoproxil fumarate or other antivirals.” According to the researchers, “tenofovir alafenamide was well-tolerated and renal and bone parameters either remained stable or improved.” The findings were published in The Lancet Gastroenterology & Hepatology.